 NEW YORK, Feb. 22, 2021 GLOBE NEWSWIRE -- Applied Therapeutics, Inc. NASDAQ: APLT the Company, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the closing of its public offering of 3,000,000 shares of its common stock, par value 0.0001 per share. The shares were offered at a price to the public of 23.00 per share, resulting in aggregate net proceeds of approximately 64.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. The offering closed on February 17, 2021. The Company granted the underwriters a 30-day option to purchase up to 450,000 additional shares of its common stock at the price to the public, less underwriting discounts and commissions, which the underwriters exercised in full on February 17, 2021 and settled on February 19, 2021. 